126 results
Page 6 of 7
8-K
EX-99.1
bfcl63 t98
27 Apr 21
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
9:31am
8-K
EX-99.1
4h6femw1 jq
26 Apr 21
VBI Vaccines Announces Presentation at the 2021 Annual Conference on About Hepatitis B
8:00am
8-K
EX-99.1
zta9 c1xtbkpgcx2
21 Apr 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
y8mq nggjbe1
12 Apr 21
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
8:00am
8-K
EX-99.1
2jf72qy4lq5o a9vs
15 Mar 21
VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference
8:00am
8-K
EX-99.1
zglp tmdx9m7
10 Mar 21
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
7:38am
8-K
EX-99.2
wmzzzbf7ltt4ilf2lkk4
10 Mar 21
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
7:38am
8-K
EX-99.1
nhvkzz w7kj
2 Mar 21
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021
8:00am
8-K
EX-99.1
48qj4byufqss or9pla
1 Mar 21
VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference
8:00am
8-K
EX-99.1
ivk4 vsrdjt6
7 Dec 20
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
10:23am
8-K
EX-99.1
5qcqlq2p2p8wvptve
27 May 20
VBI Vaccines Secures $50 Million Debt Financing From K2 HealthVentures
5:15pm
8-K
EX-99.1
hrzlhm6q9rm5l1dqfg
5 Mar 20
VBI Vaccines Provides Corporate Update, Outlook for 2020, and Year-End 2019 Financial Results
12:40pm
8-K
EX-99.1
9xkzfgsgom
10 Sep 19
Regulation FD Disclosure
8:00am
424B5
r5isc7h 4o8o1q
17 Dec 18
Prospectus supplement for primary offering
12:00am
424B5
j3j2 rbgofu
12 Dec 18
Prospectus supplement for primary offering
4:17pm